NCT05323955 2026-03-17
BRIDGET
Duke University
Phase 2 Active not recruiting
Clinical Trials
9 trialsNCT05673928 2026-01-21
A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05553522 2025-12-31
Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer
Baptist Health South Florida
Phase 1 Terminated
NCT04538742 2025-12-08
DB-07
AstraZeneca
Phase 1/2 Active not recruiting
NCT05800275 2025-11-18
ETIC-LM
UNICANCER
Phase 2 Recruiting
NCT02614794 2023-08-14
HER2CLIMB
Seagen Inc.
Phase 2 Completed
NCT04512261 2022-07-01
TOPAZ
Cedars-Sinai Medical Center
Phase 1/2 Withdrawn
NCT04760431 2021-06-02
TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT03424473 2020-02-25
Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer
Seagen Inc.
No longer available